Abdie represents life sciences and health care companies in a broad spectrum of regulatory, fraud and abuse, and transactional matters. He has experience advising clients on government drug pricing requirements, proposed federal and state drug pricing laws, and Medicare and Medicaid coverage requirements. He also regularly handles due diligence and licensure analyses for health care practice transactions and assists clients with Anti-Kickback Statute and False Claims Act investigations brought by the government.
Prior to joining Mintz, Abdie was an associate at a multinational law firm, where he handled regulatory and transactional matters for health care and pharmaceutical clients.
Abdie also maintains an active pro-bono practice, which has included working on legal issues involving compensation for veterans and immigration.
While earning his JD, Abdie served as a senior editor for the Stanford Law & Policy Review and as co-president of the Stanford Latinx Law Students Association. He also participated in the Youth and Education Law Project for the Mills Legal Clinic. In addition, he served as a government affairs intern for the Office of the Governor of Puerto Rico at the Puerto Rico Federal Affairs Administration. In that role, he conducted research on legislation, including in connection with the government of Puerto Rico’s pursuit of expanded federal health care programs for the territory.
viewpoints
Mintz IRA Update — Removal of AMP-Cap on Medicaid Rebates Causes Insulin Price Decrease
February 21, 2024 | Blog | By Bridgette Keller, Madison Castle, Abdie Santiago
Read about how the removal of the average manufacturer price (AMP) cap on Medicaid rebates prompted manufacturers to cut insulin prices to avoid significant payments to Medicaid.
Mintz IRA Update — Demystifying the IRA’s Small Biotech Exception
February 21, 2024 | Blog | By Xavier Hardy, Abdie Santiago
Read about the small biotech exception exempting certain drugs from the Medicare Drug Price Negotiation Program for the years 2026, 2027, and 2028.
Federal Judge Rejects Pharma Manufacturers’ Challenge to Negative OIG Advisory Opinion
January 22, 2024 | Blog | By Rachel Yount, Abdie Santiago
A Virginia Federal Judge recently rejected a challenge to a negative Advisory Opinion issued by the Department of Health & Human Services’ Office of Inspector General (OIG) that disapproved of a proposal where certain pharmaceutical manufacturers would fund financial assistance for the manufacturers’ Part D oncology drugs. The Advisory Opinion was requested by the Pharmaceutical Coalition for Patient Access (PCPA), which is a charitable organization formed and fully funded by pharmaceutical manufacturers of oncology drugs. Subsequently, PCPA brought the lawsuit alleging that the negative Advisory Opinion violated the Administrative Procedure Act (APA).